Clinicopathological Significance of Large Tumor Suppressor (LATS) Expression in Gastric Cancer.
- Author:
Myoung Won SON
1
;
Geum Jong SONG
;
Si Hyong JANG
;
Soon Auck HONG
;
Mee Hye OH
;
Ji Hye LEE
;
Moo Jun BAEK
;
Moon Soo LEE
Author Information
- Publication Type:Original Article
- Keywords: Stomach neoplasms; Tumor suppressor genes; LATS1 protein, human; LATS2 protein, human
- MeSH: Classification; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Joints; Long-Acting Thyroid Stimulator; Lymph Nodes; Neoplasm Metastasis; Prognosis; Stomach Neoplasms*
- From:Journal of Gastric Cancer 2017;17(4):363-373
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aims of this study were to evaluate the expression of the large tumor suppressor (LATS) genes LATS1 and LATS2 by immunohistochemical staining of gastric cancer, and to evaluate the clinicopathological significance of LATS expression and its correlation with overall survival (OS). MATERIALS AND METHODS: LATS1 and LATS2 expression in a tissue microarray was detected by immunohistochemistry, using 264 gastric cancer specimens surgically resected between July 2006 and December 2009. RESULTS: Low expression of LATS1 was significantly associated with more advanced American Joint Committee on Cancer (AJCC) stage (P=0.001) and T stage (P=0.032), lymph node (LN) metastasis (P=0.040), perineural invasion (P=0.042), poor histologic grade (P=0.007), and diffuse-type histology by the Lauren classification (P=0.033). Low expression of LATS2 was significantly correlated with older age (≥65, P=0.027), more advanced AJCC stage (P=0.001) and T stage (P=0.001), LN metastasis (P=0.004), perineural invasion (P=0.004), poor histologic grade (P<0.001), and diffuse-type histology by the Lauren classification (P<0.001). Kaplan-Meier survival analysis revealed significantly poor OS rates in the groups with low LATS1 (P=0.037) and LATS2 (P=0.037) expression. CONCLUSIONS: Expression of LATS1 or LATS2 is a significant marker for a good prognosis in patients with gastric cancer.
